Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G J Cullinan

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Journal of Medicinal Chemistry|April 1, 1979
Structure-activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfatesR A Conrad, G J Cullinan, K Gerzon, et al.
Journal of Cardiovascular Pharmacology|October 12, 2000
Raloxifene and estrogen inhibit neointimal thickening after balloon injury in the carotid artery of male and ovariectomized female ratsR F Kauffman, J S Bean, K J Fahey, et al.
Journal of Medicinal Chemistry|April 1, 1987
Leukotriene receptor antagonists. 1. Synthesis and structure-activity relationships of alkoxyacetophenone derivativesW S Marshall, T Goodson, G J Cullinan, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1984
Pharmacologic analysis of two novel inhibitors of leukotriene (slow reacting substance) releaseJ H Fleisch, K D Haisch, S M Spaethe, et al.
Journal of Medicinal Chemistry|March 1, 1989
New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activityB C Laguzza, C L Nichols, S L Briggs, et al.
The Journal of Clinical Investigation|January 1, 1994
Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized ratsL J Black, M Sato, E R Rowley, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 1997
Hypocholesterolemic activity of raloxifene (LY139481): pharmacological characterization as a selective estrogen receptor modulatorR F Kauffman, W R Bensch, R E Roudebush, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 22, 1998
LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulationC C Felder, K E Joyce, E M Briley, et al.
Journal of Medicinal Chemistry|May 9, 1997
Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulatorA D Palkowitz, A L Glasebrook, K J Thrasher, et al.
Journal of Medicinal Chemistry|January 1, 1978
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfateC J Barnett, G J Cullinan, K Gerzon, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Journal of Medicinal Chemistry|April 1, 1979
Structure-activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfatesR A Conrad, G J Cullinan, K Gerzon, et al.
Journal of Cardiovascular Pharmacology|October 12, 2000
Raloxifene and estrogen inhibit neointimal thickening after balloon injury in the carotid artery of male and ovariectomized female ratsR F Kauffman, J S Bean, K J Fahey, et al.
Journal of Medicinal Chemistry|April 1, 1987
Leukotriene receptor antagonists. 1. Synthesis and structure-activity relationships of alkoxyacetophenone derivativesW S Marshall, T Goodson, G J Cullinan, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1984
Pharmacologic analysis of two novel inhibitors of leukotriene (slow reacting substance) releaseJ H Fleisch, K D Haisch, S M Spaethe, et al.
Journal of Medicinal Chemistry|March 1, 1989
New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activityB C Laguzza, C L Nichols, S L Briggs, et al.
The Journal of Clinical Investigation|January 1, 1994
Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized ratsL J Black, M Sato, E R Rowley, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 1997
Hypocholesterolemic activity of raloxifene (LY139481): pharmacological characterization as a selective estrogen receptor modulatorR F Kauffman, W R Bensch, R E Roudebush, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 22, 1998
LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulationC C Felder, K E Joyce, E M Briley, et al.
Journal of Medicinal Chemistry|May 9, 1997
Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulatorA D Palkowitz, A L Glasebrook, K J Thrasher, et al.
Journal of Medicinal Chemistry|January 1, 1978
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfateC J Barnett, G J Cullinan, K Gerzon, et al.
Pageof 2